UBS Reiterates Neutral Rating on Incyte Corporation (INCY)

Market Context

Incyte Corporation operates in the Healthcare sector. The stock currently trades at $113.75 with a market capitalization of $18.9B. The stock has gained 21.7% over the past 52 weeks.

Analyst coverage from UBS provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Incyte Corporation.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Incyte Corporation

Among the 10 most recent ratings: 5 Buy, 5 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jun 26, 2026	UBS	Neutral	N/A
Jun 24, 2026	HC Wainwright & Co.	Buy	N/A
Jun 22, 2026	Truist Securities	Hold	N/A
Jun 22, 2026	BMO Capital	Market Perform	N/A
Jun 09, 2026	HC Wainwright & Co.	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View INCY Stock Page